AmorChem
Venture capitalMontreal · Pre-Seed–Series A · 5 people tracked
Find your way into AmorChem
Sign up to see every warm intro you have to AmorChem
- Paths you didn't know you had: your email and LinkedIn already hold routes to the AmorChem team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
AmorChem operates a venture model focused on the earliest stage of biotech creation, investing in translational research emerging from academic institutions to bridge the gap between fundamental science and commercial therapies. The fund takes a science-first approach, diving deeply into research with the goal of producing next-generation biotech companies built around novel therapeutic paradigms. Its ambition is to be Canada's premier early-stage biotech venture fund, cultivating a collaborative community of startups originating from academic research and nurturing a new generation of science entrepreneurs.
Source: firm website, verified Aug 3, 2026.
Team · 5 people
from the firm's website & public directoriesWhat they invest in
from 1 of 12 portfolio companiesAI & Machine Learning ×1Biotech ×1Digital Health ×1Medical Devices ×1
HQs:Canada×1
Investments · 12 tracked
founders shown can be your intro pathBy year:2022 · 12018 · 12 dated
Portfolio company acquired by Novo Nordisk for $1.1B USD.
Co-investorsGenesys CapitalJDRF T1D FundNew Enterprise Associates (NEA)Tarnagulla VenturesadMare BioInnovationsAmgen Ventures+2 more
Liminal BioSciences, through subsidiary CALEDON BIOSCIENCE, discovers and develops small molecule therapeutics targeting G protein-coupled receptor pathways for metabolic, inflammatory, and fibrotic diseases.
AI & Machine LearningBiotechDigital HealthMedical DevicesBelleville, CA
Bruce(Chief Executive Officer)
Co-investorsWestern Technology Investment
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Atp SynthaseGiiant PharmaKallikreinNeurasicNod2Pex1SematheraSl2Srsf3Zipcodes En
Exits · 1
1 acquisitionsInversagoacq. by Novo Nordisk
Frequently asked questions
- How many investments has AmorChem made?
- AmorChem has 12 tracked investments, 1 of which have exited.
- What stage does AmorChem invest at?
- AmorChem invests at the Pre-Seed, Seed, Series A stages.
- What sectors does AmorChem focus on?
- AmorChem focuses on Biotech, Healthtech, Medical Devices.
- Where is AmorChem located?
- AmorChem is headquartered in Montreal, CA.
- Who does AmorChem co-invest with?
- AmorChem most often shares deals with Genesys Capital, JDRF T1D Fund, New Enterprise Associates (NEA), among 5 tracked co-investors.
Images
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Blackbird is a venture capital firm that backs founders from the earliest stages, with a focus on ambitious technology startups across Australia and New Zealand.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.













.jpeg)

